Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.74 USD +2.35% Intraday chart for Lexicon Pharmaceuticals, Inc. +10.13% +13.73%
May. 02 Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02 Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M MT

Evolution of the average Target Price on Lexicon Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bfe318e17a318e2103eb01bf9.-EaH1JfSE00IDiIjptqIE8mgUHFLEMjUu5_all4vQnw.vXPmlfS1dRVZdFQal4v5Z4yNGysUWv2g89et129_B020D9PloOVgOlJnEg~fa82062a3e9562e261e0afc53a5321ef

Analyst Recommendations on Lexicon Pharmaceuticals, Inc.

Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target MT
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease DJ
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating MT
Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target MT
Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage MT
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target MT
Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating MT
LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals MT
LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept MT
LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7 MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2 MT
LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10 MT
LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold MT
LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1.74 USD
Average target price
5.25 USD
Spread / Average Target
+201.72%
High Price Target
10 USD
Spread / Highest target
+474.71%
Low Price Target
2 USD
Spread / Lowest Target
+14.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lexicon Pharmaceuticals, Inc.

Ladenburg Thalmann
Citigroup
Jefferies & Co.
Piper Sandler
Wedbush
J.P. Morgan Chase

Ratings for Lexicon Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. Consensus Lexicon Pharmaceuticals, Inc.